Business Context and Reporting Period
This Form 8-K Current Report was filed by OncoCyte Corporation (noted as Insight Molecular Diagnostics Inc. in metadata) on July 21, 2017. The company is an emerging growth company incorporated in California. The report details a material definitive agreement involving the cash exercise of existing warrants and the issuance of new warrants to certain investors.
Key Financial Metrics
- Gross Proceeds: Approximately $5.74 million received from the cash exercise of original warrants.
- Shares Issued: 1,766,923 shares of common stock issued upon the exercise of original warrants (226,923 + 540,000 + 1,000,000).
- New Warrants Issued: 1,496,923 new warrants issued to investors.
- Weighted Average Exercise Price (New Warrants): $4.34 per share.
- Original Warrant Exercise Price: $3.25 per share.
- New Warrant Exercise Prices: Either $3.25 or $5.50 per share, depending on the agreement structure.
Material Changes and Transaction Details
The company entered into three forms of Warrant Exercise Agreements with holders of warrants issued in August 2016. The transaction involved:
- Agreement 1: Two holders exercised warrants for 226,923 shares at $3.25/share. In return, they received new warrants for an equal number of shares at $5.50/share, expiring in five years.
- Agreement 2: One holder exercised warrants for 540,000 shares at $3.25/share. In return, they received a new warrant for 50% of that share count (270,000 shares) at $3.25/share, expiring in five years. The company agreed to file a resale registration statement for these shares.
- Agreement 3: One holder exercised warrants for 1,000,000 shares at $3.25/share. In return, they received two new warrants: one for 50% of the shares at $5.50/share and one for 50% at $3.25/share, both expiring in two years.
The new warrants were issued unregistered under Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D to accredited investors.
Outlook, Risks, and Management Commentary
OncoCyte intends to include the shares issuable upon exercise of the new warrants in a resale registration statement to keep them continuously effective for up to five years. The company issued a press release on July 25, 2017, announcing the closing of these transactions. The filing includes standard forward-looking statement disclaimers, noting that actual results may differ materially from anticipated results due to risk factors detailed in the company's Form 10.
Investor Verification Checklist
- Verify the total number of shares outstanding post-transaction to assess dilution impact.
- Confirm the status of the Resale Registration Statement mentioned in Agreement 2.
- Review the specific terms of the new warrants (Exhibits 4.1 through 4.4) regarding expiration dates (2019 vs. 2022) and exercise prices.
- Check the company's cash position to confirm the utilization of the $5.74 million in proceeds.
- Review the July 25, 2017 press release (Exhibit 99.1) for additional management commentary on the transaction's strategic purpose.